Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology in a COVID & Post-COVID World

Christopher Phillips, MD  |  May 11, 2020

Economic Considerations
When this crisis abates, who will be coming into our clinics? We may have the same clinic panel, but their insurance status may have changed. Some may be uninsured; some may be on Medicaid rather than commercial insurance.12 These numbers will depend on how deeply the economy contracts and how quickly it bounces back.

Do you accept Medicaid or self-pay patients? Do you have an up-to-date pay scale for self-pay patients that is fair to them and to you? If you haven’t previously accepted Medicaid patients, will this crisis change your view? There are no right or wrong answers; the mistake would be not to prepare.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Have you considered the potential burden on your pre-certification staff related to new drug prior authorizations for patients on new insurance?

If you offer health insurance, consider projections of up to a 40% increase in insurance premiums next year due to COVID-19-related costs.13 Although that’s a high-end projection, give some thought to budgeting healthcare costs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

What about volume? Due to pent-up demand, you may have a surge in patients. Do you have a staffing plan for providers and staff that may allow for increased access? Have you evaluated vacation schedules and considered adjusting them? Again, there are no right or wrong answers; it’s only wrong not to think about these possibilities. For many of us, an already long backlog of new-patient referrals will be only longer. Creative re-thinking of how we use extenders, when applicable, may be warranted and will likely play a larger role in the post-COVID-19 era.

Government Relief
Some private clinics may have applied for and obtained Small Business Association (SBA) forgivable loans. Most private clinics and larger employed groups received a share of $50 billion in HHS relief funds distributed in mid-April. The HHS funds must be used in response to COVID-19 pressures (e.g., loss of E/M and/or infusion revenue; information technology/telehealth costs related to COVID-19; staffing costs, such as staff kept on payroll who may have otherwise been furloughed, hazard and/or overtime pay, and/or training costs related to COVID-19; costs related to cleaning and personal protective equipment; fees paid to consultants, accountants or billing services related to your COVID-19 response).

If you received more than $150,000, you will need to provide an accounting each quarter of how these funds were spent. At least 75% of the SBA loan funds must be used for payroll-related expenses; the other 25% may be used for rent and utilities. Use of the funds for other purposes is not precluded, but the funds may need to be repaid at a 1% interest rate.14,15 Be sure not to double count any expenses toward both SBA and HHS funds.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Practice Support Tagged with:COVID-19Dr. Chris Phillipstelehealth

Related Articles

    Telehealth Brings Opportunities to Enhance Patient Care

    December 8, 2022

    During an ACR webinar in August, presenters discussed multiple aspects of telehealth in rheumatology, especially related to rheumatology fellowship training. They agreed that although telehealth represents one potential avenue to improve patient access to treatment for rheumatic disease, we must keep identifying the best ways to employ telehealth to enhance care. Impact of Pandemic Telemedicine…

    What’s Next for Telehealth after the COVID-19 Public Health Emergency?

    June 10, 2023

    Do you remember where you were when the COVID-19 Public Health Emergency (PHE) was declared on Jan. 31, 2020? While it may seem like yesterday, you would be forgiven for not recalling your exact location over three years ago during what felt like an incredible whirlwind for the healthcare industry. One possible location you may…

    Telerheumatology: What’s Next?

    December 17, 2020

    In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences